Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of cabozantinib in non-small cell lung cancer with MET deregulation
2017-004157-16Phase 2Active
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in non-small cell lung cancer (NSCLC), sponsored by Fondazione Ricerca Traslazionale. Primary endpoint: Response rate. Started Sep 2021; status: active.
02
Drugs
cabozantinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-004157-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004157-16.